Bionomics Initiates Phase II Clinical Trial of BNC210 for Treatment of Anxiety
PR Newswire - Mon Apr 20, 5:00AM CDT
Bionomics Limited (ASX: BNO, OTCQX: BNOEF) , a biopharmaceutical company focused on the discovery and development of innovative therapeutics for the treatment of cancer and diseases of the central nervous system, today announced the initiation of a Phase II clinical study of BNC210, the Company's drug candidate in development for the treatment of anxiety and depression.
BNO: 23.85 (-0.22)
Bionomics Showcases Oncology Drug Development Programs at 2015 AACR Annual Meeting
PR Newswire - Fri Apr 17, 5:00AM CDT
Bionomics Limited (ASX:BNO, ADR:BMICY), a biopharmaceutical company focused on the discovery and development of innovative therapeutics for the treatment of cancer and diseases of the central nervous system, today announced the presentation of data from three of its most advanced oncology programs at the upcoming American Association for Cancer Research (AACR) 106th Annual Meeting being held from April 18-22, 2015 in Philadelphia, PA USA.
BNO: 23.85 (-0.22)
BNC105 Biomarker Data to Be Presented at Asian Oncology Conference
PR Newswire - Fri Apr 10, 5:00AM CDT
Bionomics Limited (ASX: BNO, OTCQX: BNOEF) today announced that it will present a poster with new data on the DisrupTOR-1 trial of BNC105 in patients with metastatic renal cancer at the 7th Asian Oncology Summit being held from April 10-12, 2015 in Shanghai, China.
BNO: 23.85 (-0.22)
Chronic Pain Therapeutics Pipeline Review 2015 - 62 Companies & 138 Drug Profiles
M2 - Wed Mar 11, 6:50AM CDT
Research and Markets (http://www.researchandmarkets.com/research/98dtzm/chronic_pain) has announced the addition of the "Chronic Pain - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Chronic Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Pain and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AbbVie Inc. - Acadia Pharmaceuticals Inc. - Adynxx, Inc. - Akron Molecules AG - Allergan, Inc. - arGEN-X BV - Astellas Pharma Inc. - Astraea Therapeutics, LLC - AstraZeneca PLC - BCN Peptides, S.A. - BioDelivery Sciences International, Inc. - Bionomics Limited - Cara Therapeutics, Inc. - ChironWells GmbH - Chromocell Corporation - Collegium Pharmaceutical, Inc. - CoLucid Pharmaceuticals, Inc. - Convergence Pharmaceuticals Ltd. - Creabilis SA - Cytogel Pharma, LLC - Daewoong Pharmaceutical Co., Ltd. - Daiichi Sankyo Company, Limited - Dompe Farmaceutici S.p.A. - DURECT Corporation - Egalet Corporation - Eli Lilly and Company - Endo Pharmaceuticals Inc. - Glenmark Pharmaceuticals Ltd. - Grunenthal GmbH - Johnson & Johnson For more information visit http://www.researchandmarkets.com/research/98...ronic_pain
BDSI: 8.43 (-0.34), ENDP: 82.67 (-2.68), LLY: 72.81 (-0.09), DRRX: 2.43 (+0.08), AGN: 240.22 (+2.88), JNJ: 103.17 (+0.87), ACAD: 40.29 (+1.12), EGLT: 9.22 (-0.17), AZN: 68.92 (-0.37), ABBV: 65.71 (-0.28), PTIE: 2.22 (+0.02)
Bionomics Begins Trading on OTCQX Marketplace
PR Newswire - Mon Mar 02, 7:00AM CST
Bionomics Limited (ASX: BNO, OTCQX: BNOEF) today announced its ordinary shares commenced trading on the OTCQX marketplace in the U.S., effective March 2, 2015.
OTC Markets Group Welcomes Bionomics to OTCQX®
PR Newswire - Mon Mar 02, 6:00AM CST
OTC Markets Group Inc. (OTCQX: OTCM), operator of Open, Transparent and Connected financial marketplaces, today announced Bionomics Ltd. (ASX: BNO; OTCQX: BNOEF), a global biopharmaceutical company developing better treatments for cancer and central nervous system disorders, has qualified to trade on OTCQX®, the best marketplace for established, global and growth companies.